Radial ABG Sampling: A RCT of Lidocaine Local Anaesthesia
Launched by MR RYCKIE GEORGE WADE · Apr 25, 2014
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
Introduction Arterial Blood Gas (ABG) sampling is a common procedure in clinical practice, in order to obtain arterial blood for monitoring of respiratory/metabolic disease.
Normally, ABG sampling involves puncturing the radial artery with a needle and syringe. which is associated with significant pain.
Local anaesthetic agents (LA) may be infiltrated into the skin overlying the radial artery in order to reduce pain and vasospasm. LA may be in the form of topical creams or solutions for subcutaneous injection (eg. lignocaine). Similarly, LA formulations have varying concentrations of the ...
Gender
ALL
Eligibility criteria
- • Inclusion criteria All adult patients (≥18 years old) undergoing their first radial artery blood sampling as part of their normal care during hospital admission, will be included within the trial.
- • Exclusion criteria
- Patients meeting any of the below criteria will be excluded:
- • Negative Allen's test - patients with no clinically visible connection between the radial and ulnar arteries will be excluded, as compromise of the radial artery through puncture and thrombosis may theoretically result in hand ischaemia.
- • Urgent ABG - patients requiring an urgent ABG (within 20 minutes) will be unable to fully consider the participant information sheet and consent, so will be excluded.
- • GCS \<15 - patients who are not fully alert and orientated will be excluded as they cannot consent to participate and altered conscious levels may affect pain perception.
- • Prior failed ABG attempt on the contralateral limb.
- • Previous participation - this will be ascertained from the Trial folder (participants will have their JPUH Patient ID recorded).
About Mr Ryckie George Wade
Mr. Ryckie George Wade is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a background in healthcare and a focus on innovative therapeutic solutions, Mr. Wade oversees clinical studies that aim to evaluate the safety and efficacy of new treatments. His leadership ensures adherence to regulatory standards and ethical practices, fostering collaboration among research teams, healthcare professionals, and stakeholders. Through a patient-centric approach, Mr. Wade strives to contribute to the development of groundbreaking therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gorelston, Norfolk, United Kingdom
Patients applied
Trial Officials
Ryckie G Wade, MBBS MClinEd MRCS FHEA
Principal Investigator
James Paget Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials